2025年以来,云顶新耀一直站在聚光灯下。3月,全球领先的mRNA创新技术平台多点突破,不仅首款自研mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药;同时,通用型现货肿瘤治疗性疫苗EVM14获美国FDA批准临床,实现了公司自研战略的重要里程碑。5月,通过引进诞生的明星单品耐赋康 获NMPA完全批准,成为国内首个且唯一获得NMPA完全批准的IgA肾病对因治疗药物。随着2025年纳入医保目录正式...
Source Link2025年以来,云顶新耀一直站在聚光灯下。3月,全球领先的mRNA创新技术平台多点突破,不仅首款自研mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药;同时,通用型现货肿瘤治疗性疫苗EVM14获美国FDA批准临床,实现了公司自研战略的重要里程碑。5月,通过引进诞生的明星单品耐赋康 获NMPA完全批准,成为国内首个且唯一获得NMPA完全批准的IgA肾病对因治疗药物。随着2025年纳入医保目录正式...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.